氧化苦参碱对SGC-7901胃癌细胞增殖及对血管内皮生长因子表达的影响

目的研究中药苦参有效成分氧化苦参碱对SGC-7901胃癌细胞增殖及对血管内皮生长因子(VEGF)表达的影响。方法用质量浓度为0.5,1.0,2.0,4.0,8.0 g·L^-1的氧化苦参碱干预SGC-7901胃癌细胞分别为0.5,1.0,2.0,4.0,8.0 g·L^-1质量浓度实验组,无任何药物处理的SGC-7901胃癌细胞为对照组。用噻唑蓝(MTT)法检测各组SGC-7901胃癌细胞培养第1,2,3,4天的增殖情况。用1.0,2.0和4.0 g·L^-1氧化苦参碱处理SGC-7901细胞并培养48 h后,用实时荧光定量-聚合酶链式反应(RT-PCR)法检测各组VEGF mRNA的表达情况。用酶联免疫吸附(ELISA)法检测各组蛋白表达情况。结果细胞培养第4天,对照组和0.5,1.0,2.0,4.0,8.0 g·L^-1实验组的增殖抑制率分别为(4.15±3.93)%,(14.79±1.66)%,(31.65±2.07)%,(41.57±2.93)%,(64.37±4.13)%,(79.17±4.75)%,与对照组相比,各质量浓度实验组SGC-7901胃癌细胞增殖抑制率均显著升高(P<0.01)。实验组的增殖抑制率随着培养时间和药物浓度的增加而增加(P<0.05或P<0.01)。氧化苦参碱干预48 h后,对照组和1.0,2.0和4.0 g·L^-1实验组VEGF mRNA表达量分别为0.82±0.03,0.65±0.05,0.54±0.06,0.46±0.04,与对照组比较,实验组VEGF mRNA表达量明显降低,且随氧化苦参碱质量浓度的升高其VEGF mRNA表达量呈逐渐降低趋势,组间差异均有统计学意义(均P<0.01)。对照组和0.5,1.0,2.0,4.0,8.0 g·L^-1实验组上清液中VEGF蛋白表达量分别为(1326.52±139.57),(1305.69±119.88),(1235.59±102.36),(1083.33±89.65),(789.85±95.26),(426.59±83.16)pg·mL^-1,与对照组相比,2.0,4.0,8.0 g·L^-1实验组细胞上清中VEGF蛋白表达量随氧化苦参碱质量浓度的增加而逐渐降低(P<0.05)。结论氧化苦参碱可抑制SGC-7901胃癌细胞增殖,增殖抑制率与作用时间、药物浓度呈正比,同时氧化苦参碱具有抑制相关肿瘤血管生成因子表达的作用。     

体外构建人巨核祖细胞/胃癌细胞融合体生成血小板的研究

目的构建脐血巨核祖细胞/胃癌SGC7901细胞融合体产生功能性血小板。方法免疫磁珠分选人脐带血CD34+细胞,通过RPMI1640培养基体外静态培养,加入定向分化因子TPO、FL、IL-3、IL-6产生巨核祖细胞;复苏胃癌SGC7901细胞;采用聚乙二醇(PEG)化学融合法制备巨核祖细胞/胃癌SGC7901细胞融合体,HAT筛选系统分选融合细胞,继续培养;流式细胞仪检测培养孔上层液中类血小板颗粒表面CD41、CD62p表达,血小板聚集试验、粘附试验检测血小板功能,瑞氏染色观察颗粒形态。结果免疫磁珠分选的CD34+细胞培养7 d可增殖80倍,与胃癌SGC7901细胞株经PEG化学融合法融合成巨核祖细胞/胃癌细胞,融合率为(36.91±1.08)%;融合细胞培养10 d可增殖4倍,产生(6.1±1.21)×106/ml的类血小板颗粒;瑞氏染色后观察,其形态与正常血小板相似。类血小板颗粒表达血小板特异性标志CD41及血小板活化后标志CD62p,与正常血小板比较,CD62p在类血小板颗粒中表达略降低:正常血小板(74.11±1.71)%、类血小板颗粒(71.04±1.64)%;CD41表达明显降低:正常血小板(88.83±3.26)%、类血小板颗粒(72.51±2.79)%(t=6.59,P<0.05);聚集试验表明具有正常血小板相似的聚集功能;血小板粘附试验:正常血小板(40.43±1.63%)、类血小板颗粒(35.53±4.06%)。结论通过PEG细胞化学融合法构建的脐带血巨核祖细胞/胃癌SGC7901细胞融合体能产生功能性血小板。     

RAD001对胃癌SGC7901细胞生长的抑制作用及分子机制

目的:研究mTOR特异性抑制剂RAD001对胃癌SGC7901细胞增殖的影响,并探讨survivin在其中的作用.方法:常规培养胃癌SGC7901细胞,RAD001单独或联合顺铂干预,MTT法测定RAD001对胃癌SGC7901细胞增殖的影响,流式细胞术检测细胞凋亡率.免疫细胞化学和Western-blot检测药物作用...     

罗格列酮逆转人胃癌祼鼠移植瘤对丝裂霉素耐药的作用

目的观察PPARγ激动剂罗格列酮（ROS）能否逆转人胃癌SGC7901/VCR细胞裸鼠移植瘤对丝裂霉素（MMC）的耐药作用。方法建立人胃癌SGC7901/VCR细胞裸鼠移植瘤模型,将48只裸鼠随机分为6组：空白对照组（生理盐水0.2 mL灌胃）、MMC组（MMC 2.5 mg/kg腹腔注射）、ROS组（ROS100 mg/kg灌胃）、MMC＋ROS中剂量组（MMC2.5 mg/kg腹腔注射＋ROS 50 mg/kg灌胃）、MMC＋ROS高剂量组（MMC 2.5 mg/kg腹腔注射＋ROS 100 mg/kg灌胃）、MMC＋CSA组（MMC2.5 mg/kg腹腔注射＋CSA 50 mg/kg灌胃）。每组8只裸鼠;用药40天后,观察各组裸鼠体重和移植瘤体积变化,计算抑瘤率,绘制移植瘤的生长曲线;HE染色观察移植瘤的组织形态。结果处死前各组裸鼠体重差异无统计学意义（P〉0.05）;空白对照组、MMC组移植瘤瘤体积和抑瘤率差异无显著性（P〉0.05）,ROS组、MMC＋ROS中剂量组、MMC＋ROS高剂量组、MMC＋CSA组与空白对照组、MMC组比较移植瘤瘤体积和抑瘤率差异均有显著性（P〈0.05）。结论罗格列酮可抑制人胃癌SGC7901/VCR细胞祼鼠移植瘤瘤体生长,罗格列酮可部分逆转人胃癌SGC7901/VCR细胞祼鼠移植瘤对丝裂霉素的耐药性。     

Serrin B和Nodosin对HL60、SGC7901、LOVO、U87、AGZY细胞株的毒性作用

目的探讨天然药物Serrin B和Nodosin对人早幼粒白血病细胞株HL60、人胃腺癌细胞株SGC7901、人结肠癌细胞株LOVO、人胶质瘤细胞株U87、人肺腺癌细胞株AGZY的毒性作用。方法将对数期生长的HL60、SGC7901、LOVO、U87、AGZY细胞株接种于96孔板中,细胞贴壁后,分别加入Serrin B或Nodosin,使药物的终浓度分别为0.00、1.25、2.50、5.00、10.00、20.00μmol.L-1,24 h后用四甲基偶氮唑盐法检测细胞株的死亡率。结果 Serrin B对HL60、SGC7901、LOVO、U87和AGZY细胞株均有较强的毒性作用(P<0.01),且其毒性作用呈现剂量-效应关系。Nodosin对HL60、SGC7901、LOVO、U87细胞株具有较强的毒性作用(P<0.05,P<0.01),而对AGZY细胞株无明显毒性作用。结论 Serrin B和Nodosin是中药溪黄草抗癌作用的有效成分,为人类多种肿瘤治疗的新药研究开发提供新的思路。     

Calotropis gigantiea (L.) R. Br (Apocynaceae): A phytochemical and pharmacological review

Ethnopharmacological relevance

Calotropis gigantiea (L.) R. Br (Apocynaceae) commonly called as “crown flower” or “giant milk weed” is a well-known weed to many cultures for treating various disorders related to central nervous system, skin diseases, digestive system, respiratory system, reproductive system etc. Indigenous groups made the plant as a part of their lives since they use the fruit fibre to make ropes, household items, for weaving clothes and flowers for garlands apart from usage for various indications. The study aims at far-reaching review on phytochemistry, pharmacological activities, ethnopharmacology, intellectual property transfer on pharmacological therapies, toxicity which aids to provide scientific evidence for the ethnobotanical claims and to identify gaps required to be conducted as a future research prerequisite.

Materials and methods

A systematic literature search was performed using different databases such as Scopus, Science direct, PubMed and Sciverse with no timeline limit set during the search. All the available abstracts and full text articles were included in the systematic review.

Results

Most of the folkloric uses were validated by the scientific studies such as analgesic, anti-arthritic, anti-asthmatic, anti-bacterial, anti-convulsant, anti-pyretic, central nervous system disorders, contraceptive, anti-ulcer and wound healing. In addition other studies such as anti-diabetic, anti-diarrhoeal, anti-helminthic, anti-histamine, anti-inflammatory, anti-microbial, anti-oxidant, cardio-protective studies, cytotoxicity, hepatoprotectivity, fibrinolytic, mosquitocidal, nerve muscle activity, vasodilation and skeletal muscle activities were also reported for the plant. Isolated compounds such as calotropin, frugoside and 4'-O-β-d-glucopyranosyl frugoside were tested for the cytotoxicity efficacy against both human and rat cell lines out of which calotropin showed potent activity (IC₅₀–15 ng/ml). However there were no clinical trials reported on the plant which is one of the major lacunas.

Conclusions

This review article explores the ethnopharmacological, pharmacological activities phytochemistry and intellectual rights of Cg which gives the evidence of a potent and commercial drug which up on further research leads to the most viable drug for variety of treatments. However there is further need for in-vivo studies and clinical trials on isolated phytoconstituents which will help to commercialise.     

Galectin-1 is up-regulated by RASSF1A gene in human gastric carcinoma cell line SGC7901

We have previously shown that overexpression of RASSF1A inhibits the growth of human gastric cancer SGC7901 cells, but the underlying mechanism remains unknown. In this study, the differential protein expression by RASSF1A gene in human gastric cancer cell line SGC7901 was determined by 2-D gel electrophoresis combined with matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) and bioinformatics. Differential expression analysis of the protein profiles by RASSF1A gene identified a total of 35 protein spots, of which 10 were up-regulated and 25 were down-regulated. Eight proteins were identified by MALDI-TOF MS: Galectin-1, TRP-14, ACBP, PSMB5, PSMB4, TIM, vimentin, CD79α. RASSF1A up-regulated the mRNA expression of Galectin-1, TRP-14, ABCP in SGC7901. RASSF1A also led to an increased expression of Galectin-1 protein in SGC7901 confirmed by western blotting and immunocytochemistry analysis. RASSF1A inhibited the activity of NF-κB in SGC7901 cells. These data indicated that Galectin-1 may be playing a role in RASSF1A signaling in SGC7901.     

The physical state of lipid nanoparticles influences their effect on in vitro cell viability

Although lipid nanoparticles represent potent drug carriers, for many formulations toxicity data are rare. Thus, in this study, the effect of different lipid nanoparticles on the cell viability of L929 mouse fibroblasts was systematically investigated using the MTT assay. The formulations were composed of trimyristin, tristearin or cholesteryl myristate stabilized with poloxamer 188, polysorbate 80, polyvinyl alcohol or a blend of soybean phospholipid and sodium glycocholate. Depending on lipid and storage conditions, the nanoparticles were prepared in different physical states or crystal modifications leading to different particle shapes. The cell viability was influenced considerably by the physical state of the particle matrix with crystalline nanoparticles causing a stronger decrease in viability than the corresponding liquid or liquid crystalline particles. Effects on the cell viability were also related to the type of matrix lipid, stabilizer and the particle shape. However, the effects of differently shaped particles of different polymorphic modifications of crystalline tristearin were comparable. The low viability caused by poloxamer 188-stabilized particles could be correlated with a strong cell uptake which was investigated by confocal laser scanning microscopy.     

PI3K/Akt信号通路对胃癌细胞SGC7901细胞化疗效果的影响

目的运用磷脂酰肌醇3-激酶抑制剂(phosphatidylinositol 3-kinases,PI3-K)LY294002[2-(4-吗啉基)-8-苯基-4氢-1-苯并吡喃-4-酮]作用于胃癌细胞系SGC7901,探讨抑制PI3K/Akt信号转导通路对胃癌细胞化疗敏感性的影响。方法采用MTT比色法,流式细胞术检测5-FU、DDP及ADM单独或联合PI3K抑制剂LY294002对人胃癌细胞SGC7901的抑制率、凋亡率。并分析单独及联合应用LY294002对SGC7901细胞周期的影响。Western-blot检测单独及联合化疗药后P-Akt蛋白在SGC7901细胞中的表达水平。结果单独使用化疗药5-FU、DDP及ADM均可抑制SGC7901细胞增殖、诱导其凋亡。当化疗药与抑制剂联合应用,对细胞的抑制作用明显增强,促凋亡作用增强,与对照组比较(P0.05)。细胞周期同步分析显示,单独用药均可将SGC7901细胞阻滞于G0/G1期。联合使用抑制剂使处于G0/G1期细胞增加。Western blot显示化疗药上调P-Akt蛋白的表达,联合使用抑制剂后SGC7901细胞P-Akt蛋白的表达与未使用抑制剂比较减弱,差异有统计学意义(P0.05)。结论阻断PI3K/Akt信号通路可提高化疗药5-FU、DDP及ADM对胃癌细胞株SGC7901的抑制率,凋亡率并使阻滞于G0/G1期细胞增多;LY294002通过阻断PI3K/Akt信号通路,抑制P-Akt蛋白表达,增强化疗药的敏感性;LY294002阻断PI3K/Akt信号通路对5-FU、DDP、ADM治疗胃癌有一定的协同或增强作用。     

RXRγ、RARβ在9-cis-RA抑制人胃癌SGC7901细胞生长中的作用

目的:探讨维甲类X受体(RXR)γ、RARβ在RXR激动剂9-顺维甲酸(9-cis-RA)抑制人胃癌SGC7901细胞生长中的作用.方法:体外培养SGC7901细胞给予9-cis-RA干预,四甲基偶氮唑蓝(MTT)法、流式细胞术、HE染色、免疫组化染色、Western-blot检测9-cis-RA作用后SGC7901细胞生长情况、凋亡率、细胞周期的改变、RXRγ及RARβ表达情况.结果:SGC7901细胞与9-cis-RA共同培养48 h后,肿瘤细胞生长受到抑制,其作用具有浓度及时间依赖性.流式细胞仪检测显示处于G0/G1期的细胞增多,凋亡率增高,免疫组化及Western-blot 检测显示20 μmol/L 的9-cis-RA 作用72 h后,RXRγ、RARβ蛋白表达增加.结论:9-cis-RA可通过上调RXRγ、RARβ蛋白表达诱导细胞凋亡从而抑制人胃癌SGC7901细胞生长.